September 18, 2025

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB NSCLC, based on the prim...

The ASCO Post

September 18, 2025

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, ac...

The ASCO Post

September 18, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

September 18, 2025

Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response r...

The ASCO Post

September 18, 2025

JCO Authorship Guidelines Are of Benefit to Those Caring for Older Patients

The aging population, now the largest group of patients with cancer and cancer survivors, requires a rigorous and focused approach to clinical trial reporting, a need highlighted by the recent author ...

The ASCO Post

September 18, 2025

How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making

This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinic...

The ASCO Post

September 18, 2025

Oral Microbiota and Risk for Pancreatic Cancer

Oral bacteria and fungi appear to be risk factors for developing pancreatic cancer, according to findings published in JAMA Oncology. 

The ASCO Post

September 18, 2025

Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer

In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therap...

The ASCO Post

September 18, 2025

Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be wel...

The ASCO Post